Inipharm's Oral Drug Enters Key MASH Trial, Targeting Genetic Protection

BELLEVUE, WA & SAN DIEGO, CA – June 02, 2026 – In a move that underscores the rapidly evolving landscape of liver disease treatment, Inipharm has initiated dosing in a pivotal 12-week clinical study for its oral drug, INI-822. The study targets Metabolic dysfunction-associated Steatohepatitis (MASH), a severe and progressive fatty liver disease that has long represented a vast unmet medical need. This development comes at a critical juncture for the field, which only recently celebrated the first-ever FDA approval of a MASH-specific therapy, Madrigal Pharmaceuticals' Rezdiffra.

While that approval marked a watershed moment, the complexity of MASH means the race for effective, convenient, and targeted therapies is far from over. Inipharm's approach with INI-822 is particularly noteworthy, as it aims to harness a powerful, naturally occurring genetic defense mechanism against liver disease and deliver it in the form of a simple daily pill. The company is betting that this strategy can carve out a significant niche in a market desperate for better options.

The Genetic Blueprint for a Cure

The scientific foundation of INI-822 rests on one of the most validated genetic targets in modern hepatology: HSD17B13. For years, genome-wide association studies have consistently revealed a fascinating quirk in human biology. Individuals carrying certain naturally occurring genetic variants that result in an inactive HSD17B13 protein are remarkably protected from the worst outcomes of chronic liver disease. These protective variants are associated with a staggering 50% to 60% reduction in the risk of progressing from simple liver fat accumulation to the dangerous inflammation and scarring (fibrosis) that define MASH, and ultimately, cirrhosis and liver cancer.

“HSD17B13 is an increasingly well‑validated target in MASH, supported by strong human genetics,” noted Rohit Loomba, MD, chief of the Division of Gastroenterology and Hepatology at University of California San Diego School of Medicine, in the company's announcement. The goal of INI-822 is to pharmacologically mimic this natural protection by inhibiting the enzymatic activity of the HSD17B13 protein.

Crucially, this genetic shield appears to work even in individuals with the highest-risk genetic profiles. The protective HSD17B13 variant has been shown to mitigate the liver-damaging effects of the PNPLA3 I148M gene variant, a major genetic driver for MASH progression. This is a critical point of differentiation, as patients carrying this risk variant may not respond as well to other therapeutic classes, including the widely used GLP-1 agonists. By targeting a mechanism that can override a key genetic predisposition, Inipharm is pursuing a form of personalized medicine that could offer hope to some of the most vulnerable patients.

A New Horse in a High-Stakes Race

The promise of HSD17B13 has not gone unnoticed, and Inipharm is entering a competitive but strategically divided field. To date, the most advanced programs have employed RNA interference (RNAi) technology—injectable drugs designed to 'silence' the HSD17B13 gene, preventing the protein from being made. Giants like Arrowhead Pharmaceuticals (in partnership with GSK) and Alnylam (with Regeneron) have already presented promising early-stage data showing their RNAi candidates can effectively reduce HSD17B13 levels and improve liver enzyme biomarkers.

Inipharm, however, is making a strategic counter-play. INI-822 is an oral small molecule, a traditional pill format that offers a significant advantage in patient convenience over injections. But the differentiation goes deeper than just the delivery method. “We believe an oral small molecule that inhibits enzymatic activity of HSD17B13, rather than knocking it down, may better reflect the physiology of the naturally occurring protective variant,” stated Brian Farmer, CEO of Inipharm. This is a subtle but important distinction. Instead of turning off the protein's production entirely, INI-822 aims to simply block its function, an approach the company believes more closely mirrors the natural loss-of-function genetics.

While Inipharm claims INI-822 is the only small-molecule HSD17B13 inhibitor currently in clinical trials, patent filings and industry research show that other major players, including AstraZeneca and Enanta, are actively exploring the same chemical space. The race is on to prove not just that the target is valid, but which modality—injectable RNAi or oral small molecule—offers the optimal combination of efficacy, safety, and patient accessibility.

From Bench to Bedside: Designing a Trial for Success

This new 12-week, double-blind, placebo-controlled study is designed to provide the first clear glimpse of INI-822's potential in a real-world patient population. The trial will enroll approximately 50 patients with MASH and is built upon earlier, shorter-term data. “Our ongoing clinical trial of INI-822 has generated encouraging biomarker and target engagement data in MASH patients after only 28 days of dosing, demonstrating its potential to meaningfully impact the course of MASH,” said Chuhan Chung, M.D., chief medical officer of Inipharm.

Now, the company seeks to build on that initial promise. The primary focus will be on safety and pharmacokinetics, but the key readouts will come from a suite of biomarkers. Investigators will be closely watching for changes in markers of liver inflammation and, critically, for signs of improvement in fibrosis. The study will utilize FibroScan, a non-invasive ultrasound technology that measures liver stiffness, as a key tool to assess changes in scarring. Positive signals from these endpoints are essential for building the confidence needed to advance into larger, more expensive Phase 2b studies, which are typically required for regulatory approval.

The Patient and Market Imperative

Despite the breakthrough approval of Rezdiffra, the MASH market remains vast and underserved. The disease affects millions globally, and analysts predict the market for its treatments could reach tens of billions of dollars annually. No single drug is expected to be a silver bullet for all patients, creating a significant opportunity for therapies with differentiated mechanisms and profiles. An effective, safe, and convenient oral therapy like INI-822 could become a cornerstone of combination treatments or a first-line option for specific patient subgroups.

The potential to effectively treat patients with the high-risk PNPLA3 genotype is a powerful driver of value. As diagnostics become more sophisticated, physicians will increasingly look to a patient's genetic profile to guide treatment decisions. A drug that demonstrates clear benefit in this genetically-defined population would have a distinct advantage. Inipharm's 12-week study is a critical step toward determining if INI-822 can fulfill that promise, moving a compelling genetic story one step closer to a tangible clinical reality for patients.